Moxie Dwight's Form 4 filing
Revance Therapeutics, Inc. (RVNC) · filed May 16, 2023
- Accession no.
- 0001479290-23-000076
- Filed
- May 16, 2023
- Trade date
- Feb 2, 2022-May 15, 2023
- Filing delay
- 468 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $739.4K. It was filed 468 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Moxie DwightCIK 0001803375 | Officer (SVP, GC & Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2022 | Common Stock | AGrant or awardAcquired | +42,349 | $0.00 | $0 | 90,566 | Direct | |
| May 15, 2023 | Common Stock | SSaleDisposed | −21,401 | $34.55F3 | −$739,404.55 | 69,165 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.